DOCSLIB.ORG

Comprehensive Analysis of the Association Between Tumor Glycolysis and Immune/Inflammation Function in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comprehensive Analysis of the Association Between Tumor Glycolysis and Immune/Inflammation Function in Breast Cancer Li et al. J Transl Med (2020) 18:92 https://doi.org/10.1186/s12967-020-02267-2 Journal of Translational Medicine RESEARCH Open Access Comprehensive analysis of the association between tumor glycolysis and immune/ infammation function in breast cancer Wenhui Li1†, Ming Xu1†, Yu Li1, Ziwei Huang1, Jun Zhou1, Qiuyang Zhao1, Kehao Le1, Fang Dong1, Cheng Wan2 and Pengfei Yi1* Abstract Background: Metabolic reprogramming, immune evasion and tumor-promoting infammation are three hallmarks of cancer that provide new perspectives for understanding the biology of cancer. We aimed to fgure out the relation- ship of tumor glycolysis and immune/infammation function in the context of breast cancer, which is signifcant for deeper understanding of the biology, treatment and prognosis of breast cancer. Methods: Using mRNA transcriptome data, tumor-infltrating lymphocytes (TILs) maps based on digitized H&E- stained images and clinical information of breast cancer from The Cancer Genome Atlas projects (TCGA), we explored the expression and prognostic implications of glycolysis-related genes, as well as the enrichment scores and dual role of diferent immune/infammation cells in the tumor microenvironment. The relationship between glycolysis activity and immune/infammation function was studied by using the diferential genes expression analysis, gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, gene set enrichment analyses (GSEA) and correlation analysis. Results: Most glycolysis-related genes had higher expression in breast cancer compared to normal tissue. Higher phosphoglycerate kinase 1 (PGK1) expression was associated with poor prognosis. High glycolysis group had upregu- lated immune/infammation-related genes expression, upregulated immune/infammation pathways especially IL-17 signaling pathway, higher enrichment of multiple immune/infammation cells such as Th2 cells and macrophages. However, high glycolysis group was associated with lower infltration of tumor-killing immune cells such as NKT cells and higher immune checkpoints expression such as PD-L1, CTLA4, FOXP3 and IDO1. Conclusions: In conclusion, the enhanced glycolysis activity of breast cancer was associated with pro-tumor immu- nity. The interaction between tumor glycolysis and immune/infammation function may be mediated through IL-17 signaling pathway. Keywords: Breast cancer, Glycolysis, Immune/infammation function, PGK1, IL-17 signaling pathway, TCGA, Prognosis Background Breast cancer is the leading cause of cancer death among women [1]. Breast cancer can be classifed as Nor- *Correspondence: [email protected] †Wenhui Li and Ming Xu contributed equally to this work mal-like, Luminal A, Luminal B, HER2-enriched and 1 Department of Breast and Thyroid Surgery, Union Hospital, Tongji Basal-like subtypes. In addition to surgery, systemic ther- Medical College, Huazhong University of Science and Technology, apies including chemotherapy, hormonal therapy, and Wuhan 430022, China Full list of author information is available at the end of the article molecular targeted therapy can be chosen based on the © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Li et al. J Transl Med (2020) 18:92 Page 2 of 12 molecular characteristics to combat cancer [2]. Although selection. So far, however, there has been little compre- these systemic therapies have improved patients’ out- hensive analysis focusing on the relationships between comes, many patients do not respond to these existing the tumor glycolysis, immune/infammation function treatments, which leads to poor prognosis [3, 4]. On and the clinical features based on clinical data in the feld this account, some researches have been carried out to of breast cancer. Given this, we implemented studies with explore new efective therapies in breast cancer such as transcriptome and clinical data of breast cancer from Te Immunotherapy and metabolic therapy [5, 6]. However, Cancer Genome Atlas (TCGA) projects to explore the only a minority of patients beneft from these emerg- landscape of tumor glycolysis and immunity in breast ing therapies [7]. Exploring the interplay between tumor cancer, to identify the relationship between the tumor cells and tumor microenvironment could lead to deeper glycolysis and immune and infammatory cells infltra- understanding of breast cancer initiation, progression, tion, and to fgure out the impact of the two on breast and therapeutic resistance, possibly provide prospective cancer prognosis. strategies for cancer prevention and treatment [8, 9]. Metabolic reprogramming is a key hallmark of cancer Methods [10]. Te most frequently mentioned way of metabolic The preprocessing step for transcriptome and clinical data reprogramming is aerobic glycolysis. Aerobic glycolysis, We obtained mRNA transcriptome data of breast cancer also known as the “Warburg efect”, is a general way of from TCGA. Te RNA sequence data of breast cancer glucose metabolism in cancer cells. In this way, glucose is was downloaded directly from TCGA data portal (https mainly processed into lactate even when oxidative capac- ://porta l.gdc.cance r.gov/). Te obtained expression data ity is intact. Tis will lead to a highly acidic microenvi- of 19657 genes from 1208 samples including 112 normal ronment. According to current research, tumor aerobic tissues and 1096 tumor tissues were used for follow-up glycolysis can contribute to malignant transformation research. Te corresponding clinicopathological features and tumor progression [11]. Terefore, tumor aerobic including ER, PR, Her2 status, tumor stage, survival time glycolysis has possible implications for prognosis judg- and survival status were downloaded from TCGA data ment and cancer treatment [12]. Exploiting tumor gly- portal. colysis for clinical application requires fguring out how intrinsic and extrinsic factors to be integrated to modify Identifcation of diferentially expressed genes the metabolic phenotype [13]. and functional enrichment analysis Tumor microenvironment (TME), cancer cells’ sup- Te tumor samples were divided into low glycoly- porting hotbed, has complicated and changeable compo- sis group and high glycolysis group based on the median sition including tumor infltrating lymphocytes (TILs), expression of PGK1. Gene expression profles were other immune and infammatory cells, fbroblasts, the derived based on diferential genes expression analysis blood and lymphatic vascular networks, the extracellular using limma R package. Diferentially expressed genes matrix (ECM) and so on [14]. Numerous evidences sug- (DEGs) were identifed through volcano plot fltering. gest that the immune cells infltration in the TME could Te thresholds for DEGs were |log2FC| ≥ 1 and adjusted interact with tumor cells, which may afect tumor pro- P value < 0.05. Gene ontology (GO) analysis and Kyoto gression and the efcacy of existing anticancer therapies Encyclopedia of Genes and Genomes (KEGG) analysis [15, 16]. Te immune cells recruited to the tumor site were performed using DAVID (https ://david .ncifc rf.gov/) have dual characters, some can restrain carcinogenesis and WebGestalt (http://www.webge stalt .org/) [23, 24], and tumor progression while others may play a tumor- using P < 0.05 as the cut-of criterion. Gene set enrich- promoting role [17]. Tus, it is important to fgure out ment analysis (GSEA) was conducted to fnd out the the cellular heterogeneity composition of the immune signifcantly upregulated and downregulated pathways cells infltration and the cause behind it. Te results may between high and low glycolysis group using WebGestalt, be signifcant for optimizing existing treatments and using FDR < 0.05 as the cut-of criterion. identifying novel therapeutic targets [18]. Several studies have investigated the relationship Cell type enrichment analysis between tumor glycolysis and immune/infammation To evaluate the cellular heterogeneity of the tumor function [19–21]. A highly acidic microenvironment microenvironment, the xCell tool, a gene signature-based due to tumor glycolysis may diferentially infuence method, was used to fgure out the abundance of cell immune cells infltration, ultimately leading to immune types in tumor microenvironment, based on the tissue escape and cancer progression [22]. Exploration of the transcriptome profles [25]. Total 64 cell types including associations is providing a deeper look into cancer bio- adaptive and innate immune cells, stem cells, epithelial logical processes and can lead to more efective therapy
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Directed Differentiation of Human Embryonic Stem Cells Into Functional Dendritic Cells Through the Myeloid Pathway
    Directed Differentiation of Human Embryonic Stem Cells into Functional Dendritic Cells through the Myeloid Pathway This information is current as Igor I. Slukvin, Maxim A. Vodyanik, James A. Thomson, of September 24, 2021. Maryna E. Gumenyuk and Kyung-Dal Choi J Immunol 2006; 176:2924-2932; ; doi: 10.4049/jimmunol.176.5.2924 http://www.jimmunol.org/content/176/5/2924 Downloaded from References This article cites 57 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/176/5/2924.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Directed Differentiation of Human Embryonic Stem Cells into Functional Dendritic Cells through the Myeloid Pathway1 Igor I. Slukvin,2*†‡ Maxim A. Vodyanik,† James A. Thomson,†‡§¶ Maryna E. Gumenyuk,* and Kyung-Dal Choi* We have established a system for directed differentiation of human embryonic stem (hES) cells into myeloid dendritic cells (DCs).
    [Show full text]
  • Activation of PGK1 Under Hypoxic Conditions Promotes Glycolysis and Increases Stem Cell‑Like Properties and the Epithelial‑M
    INTERNATIONAL JOURNAL OF ONCOLOGY 57: 743-755, 2020 Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell‑like properties and the epithelial‑mesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway YADONG ZHANG1,2, HONGSHI CAI1,2, YAN LIAO1,2, YUE ZHU1,2, FANG WANG1,2 and JINSONG HOU1,2 1Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Guanghua School of Stomatology; 2Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong 510055, P.R. China Received January 13, 2020; Accepted April 22, 2020 DOI: 10.3892/ijo.2020.5083 Abstract. Although it has been previously documented that a study demonstrate that hypoxia can increase PGK1 expression, hypoxic environment can promote glycolysis and the malignant resulting in the promotion of glycolysis, enhancing stem progression of oral squamous cell carcinoma (OSCC) cell-like properties and EMT by activating AKT signalling in cells, the specific underlying mechanism remains unclear. OSCC. Phosphoglycerate kinase 1 (PGK1) has been previously reported to serve an important role in tumor metabolism. Introduction The aim of the present study was to investigate the effects of hypoxia and PGK1 on glycolysis, stem cell-like properties Oral squamous cell carcinoma (OSCC) is the most prevalent and epithelial-mesenchymal transition (EMT) in OSCC cells. malignant tumour in the oral and maxillofacial region (1). The Cell Counting Kit-8 assays were performed to examine tumor high incidence of oral cancer is attributed to physical, chemical cell viability under hypoxic conditions. Sphere formation, and biological factors. According to the statistics of American immunohistochemistry, western blotting, Transwell assays and Cancer Association, there were about 48,000 newly diagnosed mouse xenograft studies were performed to assess the biological cases of OSCC in 2016, which accounted for 3% of all new effects of PGK1.
    [Show full text]
  • Structures, Functions, and Mechanisms of Filament Forming Enzymes: a Renaissance of Enzyme Filamentation
    Structures, Functions, and Mechanisms of Filament Forming Enzymes: A Renaissance of Enzyme Filamentation A Review By Chad K. Park & Nancy C. Horton Department of Molecular and Cellular Biology University of Arizona Tucson, AZ 85721 N. C. Horton ([email protected], ORCID: 0000-0003-2710-8284) C. K. Park ([email protected], ORCID: 0000-0003-1089-9091) Keywords: Enzyme, Regulation, DNA binding, Nuclease, Run-On Oligomerization, self-association 1 Abstract Filament formation by non-cytoskeletal enzymes has been known for decades, yet only relatively recently has its wide-spread role in enzyme regulation and biology come to be appreciated. This comprehensive review summarizes what is known for each enzyme confirmed to form filamentous structures in vitro, and for the many that are known only to form large self-assemblies within cells. For some enzymes, studies describing both the in vitro filamentous structures and cellular self-assembly formation are also known and described. Special attention is paid to the detailed structures of each type of enzyme filament, as well as the roles the structures play in enzyme regulation and in biology. Where it is known or hypothesized, the advantages conferred by enzyme filamentation are reviewed. Finally, the similarities, differences, and comparison to the SgrAI system are also highlighted. 2 Contents INTRODUCTION…………………………………………………………..4 STRUCTURALLY CHARACTERIZED ENZYME FILAMENTS…….5 Acetyl CoA Carboxylase (ACC)……………………………………………………………………5 Phosphofructokinase (PFK)……………………………………………………………………….6
    [Show full text]
  • Ncomms4301.Pdf
    ARTICLE Received 8 Jul 2013 | Accepted 23 Jan 2014 | Published 13 Feb 2014 DOI: 10.1038/ncomms4301 Genome-wide RNAi ionomics screen reveals new genes and regulation of human trace element metabolism Mikalai Malinouski1,2, Nesrin M. Hasan3, Yan Zhang1,4, Javier Seravalli2, Jie Lin4,5, Andrei Avanesov1, Svetlana Lutsenko3 & Vadim N. Gladyshev1 Trace elements are essential for human metabolism and dysregulation of their homoeostasis is associated with numerous disorders. Here we characterize mechanisms that regulate trace elements in human cells by designing and performing a genome-wide high-throughput siRNA/ionomics screen, and examining top hits in cellular and biochemical assays. The screen reveals high stability of the ionomes, especially the zinc ionome, and yields known regulators and novel candidates. We further uncover fundamental differences in the regulation of different trace elements. Specifically, selenium levels are controlled through the selenocysteine machinery and expression of abundant selenoproteins; copper balance is affected by lipid metabolism and requires machinery involved in protein trafficking and post-translational modifications; and the iron levels are influenced by iron import and expression of the iron/haeme-containing enzymes. Our approach can be applied to a variety of disease models and/or nutritional conditions, and the generated data set opens new directions for studies of human trace element metabolism. 1 Genetics Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. 2 Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, USA. 3 Department of Physiology, Johns Hopkins University, Baltimore, Maryland 21205, USA. 4 Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
    [Show full text]
  • PTEN Deficiency Causes Dyschondroplasia in Mice By
    DEVELOPMENT AND DISEASE RESEARCH ARTICLE 3587 Development 135, 3587-3597 (2008) doi:10.1242/dev.028118 PTEN deficiency causes dyschondroplasia in mice by enhanced hypoxia-inducible factor 1α signaling and endoplasmic reticulum stress Guan Yang, Qiang Sun, Yan Teng, Fangfei Li, Tujun Weng and Xiao Yang* Chondrocytes within the growth plates acclimatize themselves to a variety of stresses that might otherwise disturb cell fate. The tumor suppressor PTEN (phosphatase and tensin homolog deleted from chromosome 10) has been implicated in the maintenance of cell homeostasis. However, the functions of PTEN in regulating chondrocytic adaptation to stresses remain largely unknown. In this study, we have created chondrocyte-specific Pten knockout mice (Ptenco/co;Col2a1-Cre) using the Cre-loxP system. Following AKT activation, Pten mutant mice exhibited dyschondroplasia resembling human enchondroma. Cartilaginous nodules originated from Pten mutant resting chondrocytes that suffered from impaired proliferation and differentiation, and this was coupled with enhanced endoplasmic reticulum (ER) stress. We further found that ER stress in Pten mutant chondrocytes only occurred under hypoxic stress, characterized by an upregulation of unfolded protein response-related genes as well as an engorged and fragmented ER in which collagens were trapped. An upregulation of hypoxia-inducible factor 1α (HIF1α) and downstream targets followed by ER stress induction was also observed in Pten mutant growth plates and in cultured chondrocytes, suggesting that PI3K/AKT
    [Show full text]
  • Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
    cancers Article Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Miriam G. Contreras Mostazo 1,2,3, Nina Kurrle 3,4,5, Marta Casado 6,7 , Dominik Fuhrmann 8, Islam Alshamleh 4,9, Björn Häupl 3,4,5, Paloma Martín-Sanz 7,10, Bernhard Brüne 5,8,11 , 3,4,5 4,9 3,4,5, 1,2,7,12, , Hubert Serve , Harald Schwalbe , Frank Schnütgen y , Silvia Marin * y 1,2,7,12, , and Marta Cascante * y 1 Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain; [email protected] 2 Institute of Biomedicine of University of Barcelona, 08028 Barcelona, Spain 3 Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe-University, 60590 Frankfurt am Main, Germany; [email protected] (N.K.); [email protected] (B.H.); [email protected] (H.S.); [email protected] (F.S.) 4 German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; [email protected] (I.A.); [email protected] (H.S.) 5 Frankfurt Cancer Institute (FCI), Goethe University, 60590 Frankfurt am Main, Germany; [email protected] 6 Biomedicine Institute of Valencia, IBV-CSIC, 46010 Valencia, Spain; [email protected] 7 CIBER of Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain; [email protected] 8 Institute of Biochemistry I, Faculty of
    [Show full text]
  • Anti-PGK1 + PGK2 Antibody (ARG40834)
    Product datasheet [email protected] ARG40834 Package: 50 μg anti-PGK1 + PGK2 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes PGK1 + PGK2 Tested Reactivity Hu, Rat Predict Reactivity Ms, Hm Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name PGK1 + PGK2 Antigen Species Human Immunogen Synthetic peptide corresponding to aa. 166-180 of Human PGK1. (FGTAHRAHSSMVGVN) Conjugation Un-conjugated Alternate Names EC 2.7.2.3; Primer recognition protein 2; PGKA; PRP 2; Phosphoglycerate kinase 1; MIG10; Cell migration-inducing gene 10 protein; HEL-S-68p Application Instructions Application table Application Dilution IHC-P 1:200 - 1:1000 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 45 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.2% Na2HPO4, 0.9% NaCl, 0.05% Thimerosal, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Thimerosal and 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol PGK1 Gene Full Name phosphoglycerate kinase 1 Background The protein encoded by this gene is a glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate.
    [Show full text]
  • Anti-PGK1 Antibody (ARG40844)
    Product datasheet [email protected] ARG40844 Package: 50 μg anti-PGK1 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes PGK1 Tested Reactivity Hu, Rat Tested Application WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name PGK1 Antigen Species Human Immunogen Synthetic peptide corresponding to aa. 312-337 of Human PGK1. (MGLDCGPESSKKYAEAVTRAKQIVWN) Conjugation Un-conjugated Alternate Names EC 2.7.2.3; Primer recognition protein 2; PGKA; PRP 2; Phosphoglycerate kinase 1; MIG10; Cell migration-inducing gene 10 protein; HEL-S-68p Application Instructions Application table Application Dilution WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 45 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.2% Na2HPO4, 0.9% NaCl, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol PGK1 Gene Full Name phosphoglycerate kinase 1 Background The protein encoded by this gene is a glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate.
    [Show full text]
  • Platelet Isoform of Phosphofructokinase Promotes Aerobic Glycolysis and the Progression of Non‑Small Cell Lung Cancer
    MOLECULAR MEDICINE REPORTS 23: 74, 2021 Platelet isoform of phosphofructokinase promotes aerobic glycolysis and the progression of non‑small cell lung cancer FUAN WANG1, LING LI2 and ZHEN ZHANG3 1Department of Surgical Group, Medical College of Pingdingshan University, Pingdingshan, Henan 467000; 2Department of Respiratory Medicine, First People's Hospital of Jinan, Jinan, Shandong 250000; 3Department of Neurosurgery, Shandong Provincial Hospital, Jinan, Shandong 250012, P.R. China Received April 2, 2020; Accepted October 19, 2020 DOI: 10.3892/mmr.2020.11712 Abstract. The platelet isoform of phosphofructokinase by western blotting. Glucose uptake, lactate production and (PFKP) is a rate‑limiting enzyme involved in glycolysis that the adenosine trisphosphate/adenosine diphosphate ratio serves an important role in various types of cancer. The aim were measured using the corresponding kits. The results of of the present study was to explore the specific regulatory the present study demonstrated that PFKP expression was relationship between PFKP and non‑small cell lung cancer upregulated in NSCLC tissues and cells, and PFKP expression (NSCLC) progression. PFKP expression in NSCLC tissues was related to lymph node metastasis and histological grade. and corresponding adjacent tissues was detected using In addition, overexpression of PFKP inhibited cell apoptosis, reverse transcription‑quantitative polymerase chain reac‑ and promoted proliferation, migration, invasion and glycolysis tion (RT‑qPCR) and immunohistochemical analysis. PFKP of H1299 cells, whereas knockdown of PFKP had the opposite expression in human bronchial epithelial cells (16HBE) and effects. In conclusion, PFKP inhibited cell apoptosis, and NSCLC cells (H1299, H23 and A549) was also detected using promoted proliferation, migration, invasion and glycolysis of RT‑qPCR.
    [Show full text]
  • PFKP Antibody A
    Revision 1 C 0 2 - t PFKP Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 2 1 Web: [email protected] 4 www.cellsignal.com 5 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP H Mk Endogenous 80 Rabbit Q01813 5214 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity PFKP Antibody detects endogenous levels of total PFKP protein. Species Reactivity: Human, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PFKP protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Phosphofructokinase (PFK) catalyzes the phosphorylation of fructose-6-phosphate in glycolysis (1). There are three isozymes: muscle-type, liver-type, and platelet-type (2,3). Platelet-type phosphofructokinase (PFKP) is expressed in various cell types (4,5). Research studies have shown that genetic variations in PFKP are associated with individuals born small for gestational age that are prone to obesity and diabetes later in adulthood (6). 1. Mediavilla, D. et al. (2008) J Biochem 144, 235-44. 2. Eto, K. et al. (1994) Biochem Biophys Res Commun 198, 990-8. 3. Hannemann, A. et al.
    [Show full text]
  • GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity
    Article GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity Graphical Abstract Authors Sharon M. Louie, Elizabeth A. Grossman, Lisa A. Crawford, ..., Andrei Goga, Eranthie Weerapana, Daniel K. Nomura Correspondence [email protected] In Brief Using a reactivity-based chemoproteomic platform, Louie et al. have identified GSTP1 as a triple-negative breast cancer target that, when inhibited, impairs breast cancer pathogenicity through inhibiting GAPDH activity and downstream metabolism and signaling pathways. Highlights d We used chemoproteomics to profile metabolic drivers of breast cancer d GSTP1 is a novel triple-negative breast cancer-specific target d GSTP1 inhibition impairs triple-negative breast cancer pathogenicity d GSTP1 inhibition impairs GAPDH activity to affect metabolism and signaling Louie et al., 2016, Cell Chemical Biology 23, 1–12 May 19, 2016 ª 2016 Elsevier Ltd. http://dx.doi.org/10.1016/j.chembiol.2016.03.017 Please cite this article in press as: Louie et al., GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity, Cell Chemical Biology (2016), http://dx.doi.org/10.1016/j.chembiol.2016.03.017 Cell Chemical Biology Article GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity Sharon M. Louie,1 Elizabeth A. Grossman,1 Lisa A. Crawford,2 Lucky Ding,1 Roman Camarda,3 Tucker R. Huffman,1 David K. Miyamoto,1 Andrei Goga,3 Eranthie Weerapana,2 and Daniel K. Nomura1,* 1Departments of Chemistry and Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA 2Department of Chemistry, Boston College, Chestnut Hill, MA 02467, USA 3Department of Cell and Tissue Biology and Medicine, University of California, San Francisco, San Francisco, CA 94143, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.chembiol.2016.03.017 SUMMARY subtypes that are correlated with heightened malignancy and poor prognosis remain poorly understood.
    [Show full text]